Therapeutic Advances in Drug Safety

Papers
(The median citation count of Therapeutic Advances in Drug Safety is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)38
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada32
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study27
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions26
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database18
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study15
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community13
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend13
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana12
Corrigendum12
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging12
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis12
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review11
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey11
Increasing patient involvement through self-administration of medication10
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study10
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study10
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience8
Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic8
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey7
Impact of risk communication on patient’s safety during the pandemic7
Artificial intelligence in drug development: reshaping the therapeutic landscape6
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology6
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations5
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward5
Flow rate accuracy of infusion devices within healthcare settings: a systematic review5
A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States5
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system5
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization4
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database4
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries4
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers4
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System4
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries4
Drug safety of frequently used drugs and substances for self-medication in COVID-194
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database4
Is there a risk of esketamine misuse in clinical practice?4
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met3
Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients3
Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity3
Inappropriate quetiapine use at a large academic medical center: frequency of misuse and associated costs of adverse effects3
Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed non-injectable opioid analgesics3
Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial3
A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease3
Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study2
The response to the COVID-19 pandemic trusted in pharmacovigilance to diminish communication risk2
Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 20202
A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)2
Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge2
Pharmacovigilance: reporting requirements throughout a product’s lifecycle2
Characterizing medication safety incidents in surgical patients: a retrospective cross-sectional analysis of incident reports2
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data2
Safety surveillance and challenges in accelerated COVID-19 vaccine development2
Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?2
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study2
Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis2
Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review2
Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis2
Determinants of COVID-19 vaccine-induced myocarditis2
Patients’ views on Self-administration of Medication during hospitalisation: a mixed-methods study1
Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis1
Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases1
Use of an electronic medication management support system in patients with polypharmacy in general practice: study protocol of a quantitative process evaluation of the AdAM trial1
Joint use of population pharmacokinetics and machine learning for optimizing antiepileptic treatment in pediatric population1
Developing and piloting a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice1
The 6th European Pharmacovigilance Congress: speaker abstracts1
Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan1
Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study1
Development of a deprescribing manual for frail older people for use in the COFRAIL study and in primary care1
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 20211
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature1
Definition of self-medication: a scoping review1
The 90% effective dose of ciprofol and propofol with S-ketamine for painless abortion: a randomized, double-blind, sequential dose-finding trial1
Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?1
Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study1
Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System1
Investigating the impact of a pharmacist intervention on inappropriate prescribing practices at hospital admission and discharge in older patients: a secondary outcome analysis from a randomized contr1
An integrative systematic review of nurses’ involvement in medication deprescription in long-term healthcare settings for older people1
0.030472040176392